CZ2003966A3 - Farmaceutický prostředek obsahující sloučeninu modafinilu v roztoku - Google Patents

Farmaceutický prostředek obsahující sloučeninu modafinilu v roztoku Download PDF

Info

Publication number
CZ2003966A3
CZ2003966A3 CZ2003966A CZ2003966A CZ2003966A3 CZ 2003966 A3 CZ2003966 A3 CZ 2003966A3 CZ 2003966 A CZ2003966 A CZ 2003966A CZ 2003966 A CZ2003966 A CZ 2003966A CZ 2003966 A3 CZ2003966 A3 CZ 2003966A3
Authority
CZ
Czechia
Prior art keywords
pharmaceutical composition
modafinil
composition according
peg
polyethylene glycol
Prior art date
Application number
CZ2003966A
Other languages
Czech (cs)
English (en)
Inventor
Martin J. Jacobs
Bradley T. Mcintyre
Piyush R. Patel
Original Assignee
Cephalon, Ing.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon, Ing. filed Critical Cephalon, Ing.
Publication of CZ2003966A3 publication Critical patent/CZ2003966A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ2003966A 2000-10-11 2001-10-11 Farmaceutický prostředek obsahující sloučeninu modafinilu v roztoku CZ2003966A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23948800P 2000-10-11 2000-10-11
US09/974,473 US6489363B2 (en) 2000-10-11 2001-10-10 Pharmaceutical solutions of modafinil compounds

Publications (1)

Publication Number Publication Date
CZ2003966A3 true CZ2003966A3 (cs) 2003-09-17

Family

ID=26932612

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2003966A CZ2003966A3 (cs) 2000-10-11 2001-10-11 Farmaceutický prostředek obsahující sloučeninu modafinilu v roztoku

Country Status (21)

Country Link
US (1) US6489363B2 (enExample)
EP (1) EP1324755B1 (enExample)
JP (1) JP2004510816A (enExample)
KR (1) KR100846914B1 (enExample)
CN (1) CN100518726C (enExample)
AT (1) ATE478662T1 (enExample)
AU (2) AU9678501A (enExample)
BG (1) BG66221B1 (enExample)
BR (1) BR0114813A (enExample)
CA (1) CA2425218C (enExample)
CZ (1) CZ2003966A3 (enExample)
DE (1) DE60142913D1 (enExample)
EA (1) EA005572B1 (enExample)
HU (1) HU229424B1 (enExample)
IL (2) IL155263A0 (enExample)
MX (1) MXPA03003150A (enExample)
NO (1) NO333096B1 (enExample)
NZ (1) NZ525166A (enExample)
PL (1) PL214879B1 (enExample)
SK (1) SK287436B6 (enExample)
WO (1) WO2002030413A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
KR100911952B1 (ko) * 2000-10-11 2009-08-13 세파론, 인코포레이티드 모다피닐 화합물을 포함하는 조성물
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
WO2004082624A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. Modafinil-based neurorehabilitation of impaired neurological function associated with injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
BRPI0500520A (pt) * 2005-02-16 2006-09-26 Henry Jun Suzuki uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas
US20090123545A1 (en) * 2005-07-21 2009-05-14 Ron Eyal S Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof
WO2008021341A2 (en) 2006-08-14 2008-02-21 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
CA2629979A1 (en) * 2008-04-25 2009-10-25 Pharmascience Inc. Novel resveratrol compositions
FR2987266B1 (fr) 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
FR2987265B1 (fr) 2012-02-28 2014-02-28 Debregeas Et Associes Pharma Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application
MX2015004973A (es) * 2012-10-18 2015-07-17 Abbvie Inc Formulaciones de compuestos derivados de pirimidindiona.
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function

Also Published As

Publication number Publication date
ATE478662T1 (de) 2010-09-15
AU2001296785B2 (en) 2006-03-16
BG107720A (bg) 2004-01-30
HUP0302478A3 (en) 2005-05-30
HU229424B1 (hu) 2013-12-30
IL155263A (en) 2007-07-24
NO20031648L (no) 2003-06-04
NZ525166A (en) 2006-10-27
HUP0302478A2 (hu) 2003-11-28
BR0114813A (pt) 2005-01-25
US6489363B2 (en) 2002-12-03
AU9678501A (en) 2002-04-22
SK287436B6 (sk) 2010-09-07
PL214879B1 (pl) 2013-09-30
SK4402003A3 (en) 2003-09-11
EA005572B1 (ru) 2005-04-28
MXPA03003150A (es) 2003-07-14
US20020099097A1 (en) 2002-07-25
DE60142913D1 (de) 2010-10-07
HK1057336A1 (en) 2004-04-02
PL361134A1 (en) 2004-09-20
CN1468096A (zh) 2004-01-14
CA2425218A1 (en) 2002-04-18
KR20030055279A (ko) 2003-07-02
NO333096B1 (no) 2013-03-04
EP1324755A1 (en) 2003-07-09
EP1324755B1 (en) 2010-08-25
CN100518726C (zh) 2009-07-29
CA2425218C (en) 2010-10-05
NO20031648D0 (no) 2003-04-10
JP2004510816A (ja) 2004-04-08
KR100846914B1 (ko) 2008-07-17
BG66221B1 (bg) 2012-06-29
EA200300450A1 (ru) 2003-08-28
IL155263A0 (en) 2003-11-23
WO2002030413A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
CZ2003966A3 (cs) Farmaceutický prostředek obsahující sloučeninu modafinilu v roztoku
ES2402544T3 (es) Preparación pelicular rápidamente soluble
KR100359556B1 (ko) 티릴라자드의조용매비경구제
AU2001296785A1 (en) Pharmaceutical solutions of modafinil compounds
BRPI0822206B1 (pt) Formulação líquida para deferiprona com um sabor agradável.
JP2006507300A (ja) モダフィニル化合物を含んでなる薬剤溶液およびさまざまな疾患を処置するための薬剤の製造のためのそれらの使用
GB2594242A (en) A stable and ready to administer liquid pharmaceutical composition of topiramate
CZ306618B6 (cs) Kompozice obsahující sloučeniny modafinylu
PL187919B1 (pl) Preparat farmaceutyczny do podawania doustnego zawierający inhibitor proteazy HIV oraz sposób wytwarzania preparatu farmaceutycznego do podawania doustnego zawierającego inhibitor proteazy HIV
ES2241777T3 (es) Composiciones farmaceuticas que contienen terbinafina.
AU2013288231B2 (en) Pediatric oral liquid compositions containing Nepadutant
ES2350740T3 (es) Soluciones farmacéuticas de compuestos de modafinilo.
HK1057336B (en) Pharmaceutical solutions of modafinil compounds
WO2024144482A1 (en) Pharmaceutical oral suspension compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
TR2025008650T2 (tr) Etki̇n madde olarak kenodeoksi̇koli̇k asi̇t (cdca) ve di̇ğer i̇lgi̇li̇ yardimci maddeleri̇ i̇çeren farmasöti̇k oral süspansi̇yon bi̇leşi̇mleri̇
KR20160090312A (ko) 조산 조건의 치료에서 사용을 위한 용량 단위의 조합
KR20250136397A (ko) 쓴맛 약물을 위한 맛 차폐제로서 비타민 e tpgs 의 용도
SK126998A3 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
OA17358A (en) Pediatric oral liquid compositions containing nepadutant.